Drugs / OncoVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02448173 | Aug 2026 → Aug 2031 expected | malignant colon neoplasm | Vaccinogen Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OncoVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02448173 ↗ |
| Modality | Vaccine | “Within 35 days following surgery, patients are immunized with OncoVAX to prevent disease recurrence” NCT02448173 ↗ |